Post

Boehringer’s obesity drug shows efficacy for liver disease

Boehringer Ingelheim’s glucagon/GLP-1 receptor dual agonist survodutide has demonstrated efficacy for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease connected with …

Novo Nordisk signs $1.46bn deal to develop molecular glue therapies

Novo Nordisk has signed a collaboration and licensing agreement with US-based biotech Neomorph to discover and develop multiple molecular glue …

Telix to expand US footprint with IsoTherapeutics acquisition

Telix Pharmaceuticals has signed an agreement to acquire US-based speciality radiopharmaceutical development and bioconjugation company IsoTherapeutics. The strategic move is set …

Gilead’s Biktarvy gains FDA expanded indication approval for HIV

Gilead Sciences has received approval from the US Food and Drug Administration (FDA) for an expanded indication for Biktarvy to …

Bristol Myers Squibb acquires RayzeBio for $4.1bn

Bristol Myers Squibb (BMS) has announced the conclusion of its acquisition of RayzeBio, a clinical-stage radiopharmaceutical company, for $4.1bn. RayzeBio is …